Late treatment study
, medRxiv, doi:10.1101/2020.03.22.20040949 (Preprint) (meta analysis - not included in the study count)
Quantifying treatment effects of hydroxych loroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)
Secondary analysis of Gautret et al. showing "modest to no impact of HC Q treatment, with more significant effects from [HC Q+AZ]".
Meta studies are not included in the percentages or study count.
Please send us corrections, updates, or comments.